Johnson & Johnson (NYSE:JNJ) Position Decreased by Mattern Wealth Management LLC

Mattern Wealth Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,178 shares of the company's stock after selling 1,845 shares during the period. Mattern Wealth Management LLC's holdings in Johnson & Johnson were worth $1,688,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter valued at $4,390,037,000. Raymond James Financial Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $1,339,878,000. GAMMA Investing LLC raised its holdings in Johnson & Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Johnson & Johnson by 134.5% in the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after acquiring an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Raymond James Financial dropped their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Price Performance

JNJ traded up $0.43 on Friday, reaching $152.44. The company had a trading volume of 9,999,068 shares, compared to its average volume of 8,019,610. The company has a fifty day moving average of $153.85 and a 200-day moving average of $153.69. The company has a market capitalization of $366.78 billion, a P/E ratio of 16.96, a PEG ratio of 2.31 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.